GLP-1 Implant Being Tested for Overweight Pets
Weight loss medications might soon extend beyond human use, potentially benefiting our animal companions.
Okava Pharmaceuticals, a California-based firm, has initiated a clinical trial involving 50 cats to assess a GLP-1-based weight loss approach. The treatment involves a small implant placed under the skin, known as OKV-119, engineered to administer medication gradually over a six-month period.
This trial, named MEOW-1, is among the pioneering studies in this field.
The company states that the treatment “is designed to mimic many of the physiological effects of fasting - improved insulin sensitivity, reduced fat mass and more efficient energy metabolism -- without requiring significant changes in feeding routines or disrupting the human-animal bond that often centers around food.”
It offers the potential to enhance a cat's life quality and promote healthy aging. Health tracking apps like Shotlee can help monitor these improvements.
Experts indicate that roughly 60% of cats in the United States are considered overweight, which elevates the risk of diabetes and other health issues.
"In veterinary medicine for the last 100 years, the only prescription we had was feed less, exercise more, and that just doesn't work for all types of obesity," Dr. Ernie Ward, a veterinarian and pet obesity expert, told CBS News.
